Trellis Bioscience, Inc.

Cellerant Therapeutics, Inc.

Rigel Pharmaceuticals, Incorporated

Ying-Ping Jiang

Lawrence M Kauvar

Krista Maureen McCutcheon

William Usinger

Minha Park

Bo Chen

Stote Ellsworth

Orit Foord

Holger Karsunky

Fen Zhang

Gizette Sperinde

Leonard G Presta

Esteban Masuda

Naoya Tsurushita

Jagath Reddy Junutula

Haoran Zhao

X Charlene Liao

Peter Chu

Congfen Li

Jorge Pardo

Collin Spencer

Krista Maureen Mccutcheon

Provided herein are humanized antibodies specific for CLL-1.

Humanized anti-CLL-1 antibodies

Monoclonal antibodies and fragments thereof that are crossreactive with multiple clades of influenza virus including both Group 1 and Group 2 representatives are disclosed. These antibodies are useful in controlling influenza epidemics and pandemics as well as in providing prophylactic or therapeutic protection against seasonal influenza.

Antibodies useful in passive influenza immunization

Provided herein are antibodies specific for TIM3 that can be used to detect cancer cells, in particular, cancer stem cells. The antibodies can also be used in therapeutic compositions for treating cancer and reducing inflammation.

Antibodies that specifically bind to TIM3

Recombinant monoclonal antibodies to human cytomegalovirus (CMV) gB protein are described. The affinities of these antibodies are higher than the best previously reported antibodies. Since high affinity is critical to prevention of virus transfer across the placenta, the invention antibodies are useful as therapeutic and prophylactic agents to prevent or ameliorate effects on the fetus of CMV infection during pregnancy.

High affinity human antibodies to human cytomegalovirus (CMV) gB protein

High affinity human antibodies to human cytomegalovirus (CMV) GB protein

Antibodies to human Cytomegalovirus (CMV) gB protein have been isolated from human B cells. The affinities of these antibodies are higher than the best previously reported antibodies. Since high affinity is critical to prevention of virus transfer across the placenta, the invention antibodies are useful as therapeutic and prophylactic agents to prevent or ameliorate effects on the fetus of CMV infection during pregnancy.

The present invention relates to regulation of lymphocyte activation and migration. More particularly, the present invention is directed to nucleic acids encoding EDG family GPCR proteins, e.g., EDG-1, 2, 3, 4, 5, 6, 7, or 8, which are involved in modulation of lymphocyte activation and migration. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, sphingolipid analogs, and ribozymes, that modulate lymphocyte activation or migration via modulation of EDG GPCRs and EDG related signal transduction; as well as to the use of expression profiles and compositions in diagnosis and therapy related to lymphocyte activation and suppression, and lymphocyte migration.

EDG: modulators of lymphocyte activation and migration

Growing community of inventors

Lafayette, CA, United States of America

Ying-Ping Jiang